Benchmark analyst Bruce Jackson lowered the firm’s price target on CapsoVision (CV) to $10 from $14 and keeps a Speculative Buy rating on the shares after the company reported Q4 results and provided a business update. Afterwards, the firm’s new 2026 revenue estimate is $15.8M, down from $19.7M, and its new 2027 revenue estimate is $23.3M, which it notes assumes a launch of CapsoCam Colon in the second half of 2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CV:
- CapsoVision price target raised to $11 from $7 at Roth Capital
- CV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- CapsoVision jumps over 20% after announcing preliminary Q4 revenue
- CapsoVision Raises Capital and Refocuses Colon Capsule Strategy
- CapsoVision announces $14M private placement financing